AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia
22/09/2021 – AB Science today announced that its clinical trial with AB8939 in adult patients with relapsed/refractory acute myeloid leukemia (AML) has been approved by Health Canada